Human RAP 1 specifically protects telomeres of senescent cells from DNA damage

Liudmyla Lototska, Jia-xing Yue, M.J. Giraud-Panis, Zhou Songyang, Nicola Royle, Gianni Liti, Jing Ye, Eric Gilson, Aaron Mendez-bermudez

To cite this version:

Liudmyla Lototska, Jia-xing Yue, M.J. Giraud-Panis, Zhou Songyang, Nicola Royle, et al.. Human RAP 1 specifically protects telomeres of senescent cells from DNA damage. EMBO Reports, EMBO Press, 2020, 21 (4), 10.15252/embr.201949076. hal-03013736

HAL Id: hal-03013736

https://hal.archives-ouvertes.fr/hal-03013736

Submitted on 23 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Human RAP1 specifically protects telomeres of senescent cells from DNA damage

Liudmyla Lototska¹,²,†, Jia-Xing Yue²,†, Jing Li²,†, Marie-Josèphe Giraud-Panis², Zhou Songyang³,⁴,⁵, Nicola J Royle⁶,‡, Gianni Liti⁷, Jing Ye¹,*, Eric Gilson¹,²,⁷,**, & Aaron Mendez-Bermudez¹,²,#,***,‡

Abstract

Repressor/activator protein 1 (RAP1) is a highly evolutionarily conserved protein found at telomeres. Although yeast Rap1 is a key telomere capping protein preventing non-homologous end joining (NHEJ) and consequently telomere fusions, its role at mammalian telomeres in vivo is still controversial. Here, we demonstrate that RAP1 is required to protect telomeres in replicative senescent human cells. Downregulation of RAP1 in these cells, but not in young or dividing pre-senescent cells, leads to telomere uncapping and fusions. The anti-fusion effect of RAP1 was further explored in a HeLa cell line where RAP1 expression was depleted through an inducible CRISPR/Cas9 strategy. Depletion of RAP1 in these cells gives rise to telomere fusions only when telomerase is inhibited. We further show that the fusions triggered by RAP1 loss are dependent upon DNA ligase IV. We conclude that human RAP1 is specifically involved in protecting critically short telomeres. This has important implications for the functions of telomeres in senescent cells.

Keywords chromosome fusions; non-homologous end joining; RAP1; replicative senescence; telomeres

Subject Categories Autophagy & Cell Death; DNA Replication, Recombination & Repair

DOI 10.15252/embr.201949076 | Received 14 August 2019 | Revised 26 January 2020 | Accepted 29 January 2020 | Published online 25 February 2020

EMBO Reports (2020) 21: e49076

Introduction

Mammalian telomeres are composed of tandem arrays of the TTAGGG repeat sequence ending with a G-rich single-strand overhang. Over the course of evolution, mammalian telomeres invented the shelterin complex, a very elegant way to protect chromosome extremities from various DNA damaging insults, including telomere fusion events. In humans, shelterin is composed of six specialized proteins. TRF1 and TRF2 proteins bind the double-stranded part of the telomeres, while POT1 binds the single-stranded portion and interacts with TPP1 through TIN2. Finally, RAP1, one of the most evolutionarily conserved shelterin proteins, binds to telomeric DNA via its interaction with TRF2 [1,2].

In budding yeast, Rap1 protects the chromosome ends against classical non-homologous end joining (c-NHEJ) [3]. It can do so either through its C-terminal RCT domain directly or via recruitment of two other proteins, Sir4 and Rif1 [4]. Although yeast Rap1 is a key anti-fusion protein, conflicting results regarding its role as an anti-fusion factor in mammals have been reported. Indeed, mouse and human telomeres lacking Rap1 did not develop DNA damage response activation [5,6] but were prone to recombination by homology-directed repair [5]. As an outcome, this can trigger telomere resection and fusions [7]. In this regard, Rai and co-workers identified that the N-terminal BRCT and the central MYB domains of Rap1 are important to prevent telomere-free fusions and signal-free ends. They showed that Rap1 in cooperation with its interacting partner TRF2 is required to fully repress PARP1 and SLX4 localization at telomeres and further 1-loop resolution and telomere loss due to circle-mediated excision [7].

In vitro, human RAP1 has been shown to protect against NHEJ in cooperation with TRF2 [8–10]. Furthermore, it was demonstrated in vivo that artificially targeting RAP1 to telomeres in a TRF2-independent manner can mediate NHEJ [9]. Recently, Martinez and colleagues [11] have shown in mice that upon telomerase dysfunction, RAP1-deficient mice suffer from telomere end-to-end fusions and telomere loss. An emerging view is that RAP1 acts as a backup
anti-fusion factor in mammalian cells when its interacting partner TRF2 is dysfunctional but still bound to telomeres [12].

In this study, we present strong evidence that human RAP1 protects critically short telomeres. RAP1 prevents the accumulation of 53BP1 (p53-binding protein 1) at telomeres as well as protects them from fusions in senescent cells but not in cells that are actively dividing. In addition, we show that HeLa cells require RAP1 to protect their telomeres only upon telomerase inhibition, when telomeres get shorter. We further show that telomere fusion events are generated through the classical NHEJ pathway.

Results and Discussion

**RAP1 is required for telomere protection in senescent fibroblasts**

We passaged human primary lung fibroblasts (MRC-5) at 5% oxygen and we performed Western blotting at different population doublings (PDs) to determine the levels of RAP1 and TRF2 expression in young (PD 26), pre-senescent (PD 66), and senescent cells (PD 72) (Fig 1A). We defined a cellular culture as senescent when the number of cells did not increase for at least 4 weeks, SA-β-galactosidase (SA-β-Gal) activity was detected, and EdU incorporation accounted for < 1% of cells. As expected from replicative senescent cells and aging animal models, the levels of TRF2 greatly decreased (around 80%) in senescent cells [13–15]. However, the levels of RAP1 barely changed with a mild decrease of only 15% as seen previously [16,17].

In order to investigate the presence of TRF2 and RAP1 specifically at telomeres of senescent fibroblasts, we performed chromatin immunoprecipitation (ChiP) in MRC-5 cells with either anti-RAP1 or anti-TRF2 antibodies. The immunoprecipitate (IP) product was spotted on nylon membranes, and it was hybridized with a radioactively labeled telomere probe. We normalized the signal of the IP to that of the input to take into account the loss of telomere repeats during replicative senescence and thus to estimate the density of proteins bound along telomeric DNA. The density at telomeres of both TRF2 and RAP1 was reduced in senescent cells (PD 72) as compared to young cells (PD 30), but it was still detectable (Fig 1B). Interestingly, the density of telomere-bound RAP1 is reduced by only twofold in senescent cells compared to a reduction of more than fourfold for TRF2. This apparent discrepancy could stem from differences in the binding of RAP1 to TRF2 across the telomeric array.

It is possible that RAP1 binds preferentially the molecules of TRF2 found at the end of the telomeric array.

Next, we asked whether RAP1 is required for telomere protection during replicative senescence. To do so, we used an shRNA against RAP1 in MRC-5 cells of different population doublings (Fig EV1A) and we monitored telomere protection by analyzing the co-localization between 53BP1, a DNA damage response (DDR) protein, and a telomeric PNA probe (telomere dysfunction-induced foci, TIF assay) (Fig 1C). The frequency of TIFs increases with accumulating cell divisions as previously reported [18–21]. In agreement with previous studies failing to detect telomere dysfunction upon RAP1 disruption [5,6,22], RAP1 downregulation in young and pre-senescent cells did not increase the amount of TIFs. However, inhibition of RAP1 in senescent cells significantly increased TIF levels, showing that RAP1 protects telomeres against DNA damage checkpoint activation in senescent cells (Fig 1C). This increase was observed either by using lentivirus expressing an shRNA or by transient transfection of siRNAs. Notably, telomere damage was rescued by ectopic expression of RAP1, ruling out an off-target effect in our experimental settings.

Then, we measured total levels of damage by counting the number of 53BP1 spots in the cells and, as expected, total damage increased progressively as the cells approach senescence; however, RAP1 downregulation did not change the overall levels of damage, indicating the effect of RAP1 is telomere-specific (Fig 1C).

Importantly, RAP1 loss did not induce mean telomere length shortening, as revealed by Southern blotting, nor critically short telomeres, as revealed by the PCR-based STELA method (Fig EV1B and C). Thus, the increase of TIFs is unlikely to be the consequence of an excess of telomere shortening in RAP1-compromised cells. Together, these results show that the protective role of RAP1 is specific of senescent cells, as compared to dividing (young or pre-senescent) cells.

**RAP1 prevents telomere fusions in senescent fibroblasts**

Next, we investigated whether RAP1 protects telomeres of senescent cells from end-to-end fusions by means of a PCR-based method that relies on the use of subtelomeric DNA primers to amplify fusions between different chromosome ends (Fig EV2A) [23,24]. We performed PCRs with a set of three different subtelomeric primers that bind to the ends of approximately 22 chromosomes. We found a very low number of telomere fusions in young and pre-senescent fibroblasts that remained nearly unchanged upon RAP1
Figure 1.
Figure 2.
downregulation. In contrast, we found a significant fusion frequency increase in senescent cells which increase to even higher levels when RAP1 was depleted (Figs 2A and B, and EV2B and C) showing that RAP1 prevents fusion events in particular of senescent cells.

Next, we asked whether the fusions were the result of the classical or alternative NHEJ pathway by depleting cells of either DNA ligase IV (LIG4) or DNA ligase III (LIG3) (Figs 2C and D, and EV2D) [25]. Only cells downregulated for LIG4 did not increase fusion frequencies upon RAP1 inhibition showing that the fusions triggered by RAP1 loss are dependent on the classical NHEJ pathway.

In order to dissect which RAP1 domain(s) protect(s) senescent fibroblasts against fusions, we generated mutants of RAP1 that were lacking either the TRF2-binding site of RAP1 (RCT) or the Myb domain of the protein and transduced them (or the full-length protein) together with a lentivirus expressing an shRAP1 sequence domain of the protein and transduced them (or the full-length protein) together with a lentivirus expressing an shRAP1 sequence. These results show that RAP1 protects critically short telomeres in replicative senescence cells. However, this does not exclude that in other situations, e.g., in cancer cells, critically short telomeres are protected by RAP1.

**RAP1 protects critically short telomeres from fusions in HeLa cells**

Then, we asked whether the telomere protective role of RAP1 seen in senescent cells is indeed due to the presence of critically short telomeres and/or to the particular context of cellular senescence. Thus, we investigated the RAP1-protective role by using a HeLa cell line containing a doxycycline-inducible CRISPR knockout of RAP1 [26]. We treated cells for 25 days with the telomerase inhibitor BIBR1532, thus creating short telomeres, and with doxyccycline for 15 days to achieve the depletion of RAP1 (Fig 4A). As expected, BIBR1532 treatment caused a decrease in telomere length (Figs 4B and EV3A) and similar to MRC-5 senescent cells, no further telomere shortening was observed when RAP1 was depleted (Fig EV3B). Upon RAP1 depletion, there is an increase in fusion frequency only in HeLa cells treated with BIBR1532 as measured by either the PCR-based strategy used in senescent cells (Fig 4C) or counting telomere abnormalities in telomere-stained metaphase spreads (Fig 4D and E). Notably, in metaphases, we did not observe an increase of telomere fragility (as recorded by multiple telomere signal (MTS)) nor telomere loss upon RAP1 downregulation.

Once again, and in agreement with the MRC-5 results, depletion of LIG4 but not of LIG3 prevents the appearance of fusions in RAP1-compromised cells (Figs 4C and EV3C and D). Finally, we asked whether the increase in fusions upon RAP1 depletion was due to a 3' overhang trimming. However, we were unable to detect any change in the length of the overhang in HeLa cells upon RAP1 depletion and BIBR1532 treatment (Fig EV3E), indicating that RAP1...
Figure 3.
Figure 4.

A

|          | DOX | - | + | - | + |
|----------|-----|---|---|---|---|
| BIBR1532 | -   | - | + | + | + |

RAP1
Tubulin

100% 10% 100% 5%

B

|          | DOX | - | + | - | + |
|----------|-----|---|---|---|---|
| BIBR1532 | -   | - | + | + | + |


C

Number of fusions per µg of DNA

D

End-to-end fusions
Multiple telomere signal
Telomere loss
Sister chromatid fusions

E

% of end-to-end fusions
% of multiple telomere signal
% of telomere loss
% of sister chromatid fusions

© 2020 The Authors
EMBO reports 21: e49076 | 2020 7 of 14
does not change the regulation of the 5' end resection to prevent fusions. However, we cannot rule out telomere overhang loss after RAP1 depletion of only a subset of chromosomes containing very short telomeres.

Martinez and colleagues [11] showed that RAP1 has a protective role on mouse telomeres in Terc−/− mice. In contrast to our cellular settings, telomere shortening was accelerated in the double knockout mice (Terc−/−, Rap−/−) as compared to Terc−/−, giving rise to an increased number of telomere aberrations such as signal-free ends, MTS, telomere sister chromatid exchanges, and end-to-end fusions. Thus, together with our results, mammalian RAP1 appears to have the capability to protect against telomere fusions in vivo by different mechanisms including NHEJ inhibition between critically short telomeres (this study) and prevention of fusogenic telomere-free ends [7].

Overall, our results indicate that human RAP1 is required to protect critically short telomeres from classical NHEJ-mediated fusions in senescent or cancer cells. Previously, we showed that HeLa cells expressing a TRF2 mutant named “Top-less” that is unable to form t-loops activate the ATM checkpoint and rely on RAP1 to protect telomeres from fusions [12]. Altogether, we propose that RAP1 is required to protect telomeres that are too short to be able to fold into a t-loop but still capable to bind TRF2. This model is further supported by the fact that both TRF2 and RAP1 are detectable at telomeres of senescent cells (Fig 1B). Interestingly, RAP1 in senescent cells does not only protect against telomere fusion but also against 53BP1 recruitment to telomeres (Fig 1C). Since 53BP1 promotes NHEJ by increasing chromatin mobility [27,28] and/or by preventing end resection thanks to its interaction with RIF1 and the shieldin complex [29,30], it is tempting to propose that the anti-fusion properties of RAP1 rely on its ability to prevent 53BP1 binding to telomeres.

Reversal of senescence is compromised upon RAP1 depletion

A prediction of the above results is that cells bypassing the replicative senescence checkpoint would strongly rely on RAP1 for their telomere protection. In order to address this point, we took advantage of the fact that the cell-cycle arrest of replicative senescent MRC-S cells can be reversed by inhibiting the p53-p21CIP1 tumor suppressor pathway [31]. Thus, we infected senescent MRC-S cells with either an shRNA against p21CIP1 (shp21CIP1) or shp21CIP1 + shRAP1 (Fig 5A and B). Two weeks post-infection, about 66% of the shp21CIP1-transduced cells were dividing as compared to only 9% in shp21CIP1 + shRAP1 cells (Fig 5C). Even more, around 92% of the cells were positive for senescence-associated β galactosidase (SA-β-gal) staining (Fig 5D). However, as can be appreciated in the growth curve (Fig 5A), shp21CIP1 + shRAP1 cells undergo high levels of cell death. In order to investigate this further, we measured the levels of apoptosis in our cultures (Fig 5E and F). Interestingly, RAP1 depletion in cells that return to growth caused significantly higher levels of apoptosis compared to control cells (Fig 5E and F), more likely by the excess of telomere and chromosome instability.

Overall, our results together with the fact that RAP1 is a highly conserved telomere protein raise the question of the physiological role of the protection properties of RAP1 toward critically short telomeres. One possibility is that RAP1 guarantees the stability of critically short telomeres that may occur on stochastically basis during cell division [32]. In senescent cells or cells approaching senescence, it might also be important to prevent telomere fusion in order to reduce the risk of aberrant chromosome rearrangement in the event of checkpoint bypass.

Figure 4. Telomere fusions in HeLa cells after RAP1 depletion.
A RAP1 expression in HeLa cells treated with the telomerase inhibitor BIBR1532 for 25 days (20 μM final concentration). Fifteen days before cell harvesting, doxycycline (DOX, 1 μg/μl final concentration) was added to deplete the expression of RAP1.
B Telomere length analysis by Southern blotting of the samples described in (A) The size of the main intensity peak is indicated at the bottom of the gel.
C Number of fusions in HeLa cells after 25 days in culture. Cells were maintained with BIBR1532 during the whole period of the experiment, while doxycycline (1 μg/μl final concentration) and the infection with shControl, shLIG3, or shLIG4 were carried out for the last 15 days of the experiment. Data represent mean ± SD of three biological replicates. Statistical analyses were performed using Mann–Whitney U-test (*P < 0.05; **P < 0.001; ***P < 0.0001).
D Examples of metaphase spreads hybridized with a telomeric PNA probe (green) when RAP1 was depleted (+DOX). Telomerase was inhibited with BIBR1532 for 25 days. Scale bar = 10 μm.
E Quantification of chromosome aberrations observed in RAP1-depleted cells (+DOX) or control (-DOX). Data represent mean ± SD of three biological replicates. Approximately 15 metaphase spreads were analyzed per replicate with a total of 2,300 chromosomes examined per condition. *P < 0.05; two-tailed Student’s t-test.

Figure 5. RAP1 depletion in post-senescent MRC-S cells.
A Growth curve of MRC-S fibroblasts. Cells were grown until senescence and after 3 weeks of no growth detection, lentiviral infections containing either shp21CIP1 or shp21CIP1 + shRAP1 sequences were performed. Cells were harvested 15 days post-infection (dpi). Data represent mean ± SD of three biological replicates measured after 8 and 15 dpi.
B Expression of p21CIP1 and RAP1 after 15 dpi of cells transduced with shControl, shp21CIP1, or shp21CIP1 + shRAP1.
C Dividing cells (magenta) were identified by EdU staining (1 μM EdU for 24 h). The percentage of dividing cells after 15 dpi is shown (n = 3). Scale bar = 10 μm.
D Senescence-associated β-galactosidase (SA-β-gal) staining in senescent and post-senescent fibroblasts (1 and 15 dpi) is shown. Percentage of SA-β-gal-positive cells is indicated for each condition. Three biological replicates were performed, with approximately 300 cells analyzed per condition. Scale bar = 50 μm.
E Senescent cells, transduced with shp21CIP1 or shp21CIP1 + shRAP1 for 15 days, were stained with CytoCalcine violet (live cells), Apopxin Green (apoptotic cells), and 7-aminoactinomycin D (7-AAD) (late apoptotic/necrotic cells) and visualized by flow cytometry.
F Quantification of apoptotic cells from the conditions described in (E). Data represent mean ± SD of three biological replicates (***P < 0.001, two-tailed Student’s t-test).
Figure 5.

**A**

Cumulative PDs over days in culture for shp21CIP and shp21CIP+shRAP1.

Entry into senescence and Lentivirus infection are indicated.

**B**

Western blot analysis of p21CIP and RAP1 in shCtrl, shp21CIP, shp21CIP+shRAP1 conditions. Tubulin as a loading control.

**C**

Immunofluorescence images of shControl, shp21CIP, and shp21CIP+shRAP1 at 1 day and 15 days post-infection.

**D**

H&E stained images of shControl, shp21CIP, and shp21CIP+shRAP1 at 1 day and 15 days post-infection.

**E**

Flow cytometry analysis of apoptosis and necrosis in shp21CIP and shp21CIP+shRAP1 conditions.

**F**

Bar chart showing apoptotic cells (% total) for shp21CIP and shp21CIP+shRAP1 conditions. **p < 0.01 (Student's t-test).**
Materials and Methods

Cell lines and reagents

MRC-5 human primary lung fibroblasts were obtained from ATCC. MRC-5 cells were grown in DMEM supplemented with 10% fetal bovine serum, penicillin (100 IU/ml), and streptomycin (100 μg/ml). Cells were cultured at 37°C, 5% CO₂, 5% O₂. HeLa CRISPR/Cas9 engineered cell line with the doxycycline-inducible knockout of RAP1 was a gift from Dr. Songyang [26]. Cells were grown in DMEM with 10% tetracycline-free serum. To induce knockout of RAP1, cells were treated for 15 days with doxycycline (2 μg/ml, Sigma). Telomere shortening was selectively induced by treatment with the telomerase inhibitor BIBR1532 (20 μM, Merck).

Lentivirus infection and siRNA transfection

Lentiviruses were produced by transient calcium phosphate transfection of 293T cells with the virus packaging plasmids, p8.91 and pVSVg, as well as with the lentiviral expression vector that contained the sequence of interest. Titration was performed approximately 10 days after infection by means of puromycin (1 μg/ml) selection of clones.

The following shRNA plasmids were purchased from Sigma and used for lentivirus production: pLKO-shControl, pLKO-shTERF2IP, pLKO-shp21CIP1, pLKO-shLIG3, and pLKO-shLIG4 (sequences below).

Several truncated RAP1 proteins were designed using the full-length pWPIR-RAP1WT-GFP construct as a template. pWPIR-RAP1ARCT-GFP (Δ271–330 amino acids) and pWPIR-RAP1AMYB-GFP (Δ132–183 amino acids) synthesis was performed by GenScript (Piscataway, USA).

Infection with various shRNAs or overexpression vectors was performed for a minimum of 4 days, and depending on the experiment, cells were kept in culture for up to 10–15 days after infection (10 days for telomere fusion assay in MRC-5, 8–15 days—for post-senescent cells).

siRNAs were purchased from Dharmacon, and transfections were performed by DharmaFECT1 transfection reagent (Dharmacon) for 6 days by performing 2 sequential transfections of 3 days each. Efficiency of each shRNA and siRNA was checked routinely by RT–qPCR or Western blotting.

Sequences of shRNA and siRNAs used in this work are as follows: shLIG3: CGCCGCGGATCATGTTCAGAAAATCTCGAGATTTCGAGAACATGATCCGGTTTGGT shLIG4: CGCGTTGCAGCCACACCGTTATTTTCTCAGAATAAACGG TGTGGCCGCTAATTTTGT shRAP1: CGCGAGAGATGTGAAGGAAGAAATCTCGAGATTTCGAGA CTTCACATACTCTTTTTGT shp21: CGCGGCGGACTGTGATGCCGCTATCCGAGATTAGCGCA TCCAGATGCTAGTTTGTGTA shiRAP1: GAUGAGAGCAACCCUCCUGAUU shiLIG3: GCAAAAAGAUGGAGAUGU shiLIG4: GGACUUGGCUGACAUGUA

Antibodies

The following antibodies were used for Western blotting: rabbit polyclonal anti-RAP1, 1:5,000 (Bethyl Laboratories, Inc., A300-306A), rabbit polyclonal anti-TRF2, 1:5,000 (Novus Biologicals, NB110-57130), mouse monoclonal anti-α-tubulin, 1:2,000 (Merck, T9026), rabbit polyclonal anti-GAPDH, 1:1,000 (Novus Biologicals 100-56875), mouse monoclonal anti-p21, 1 μg/ml (Abcam, ab16767), rabbit polyclonal anti-DNA ligase III 1:500 (Abcam, ab185815), rabbit polyclonal anti-DNA ligase IV 1:1,000 (CST, 146495), HRP goat anti-mouse IgG, 1:10,000 (Vector Laboratories, PI-2000), and HRP goat anti-rabbit IgG, 1:10,000 (Vector Laboratories, PI-1000). Antibodies used for immunofluorescence were as follows: rabbit polyclonal anti-RAP1, 1:250 (Novus Biologicals, NB100-305) and goat anti-rabbit Alexa 488 antibody, 1:400 (111-545-144; Jackson ImmunoResearch). Antibodies used for ChIP were as follows: rabbit polyclonal anti-TRF2 (Novus Biologicals, NB110-57130) and rabbit polyclonal anti-RAP1 (Bethyl Laboratories, Inc., A300-306A), IgG control (Merc, L-5006).

Primers

The following primers were used for RT–qPCR: TERF2IP-F: CCTAGGTGTCAGAGTCTAG, TERF2IP-R: CTGGTAGTTCTGCTCAT, 2164-F: AAACGCTATTCCGCTTCTCT, 2164-R: ACTCGTTTGATCGTGTATG, p21CIP1-F: AATTCCAGACACACTAGGACCCTGA, LIG3-F: GTAC GTG CCA CCT ACC TTG T, LIG3-R: GCC GTA TGA CAC ACA GAA CCG T, LIG4-F: CAC CTT CCC TTT ACC ACG AA, and LIG4-R: CAG ATG CCT CCC TAA GTT G.

Primers used for telomere fusion assay were as follows [described in (24)]: 21q1: 5′-CTTGGGTGAGCTTAGAGAGGA-3′, 16p1: 5′-TGGACTTCTCACCCTTGAGGACGAG-3′, and XpYpM: 5′-ACCACTTGGTTTCCAGTTGTTT-3′.

Primers for the generation of subtelomeric DNA probes were as follows: XpYpO: 5′-CTTGGTAGAGCTTAGAGAGGA-3′, XpYpG: 5′-AAATCCCAGCACACTAGGACCCCTGA-3′, 21qseq1rev: 5′-TGGTCTTATA CACTGTTGTT-3′, 21qseq1rev: 5′-ACTGTTCTACTACTCTATACACA GAGC-3′, 16p2: 5′-TCACTGCTTGATCTCCCAGTG-3′, and 16pseq1rev: 5′-GCTGGGTTAGCTTATTGAGAAGAAGC-3′.

Primers used for STELA were as follows [described in (33)]: XpYpE2: TTCTGCTACCGGGCATTAGT, telotere: TGCTCGTGCAT CTCGGCATTACCCGCT-, and teltail: TGCTCGTGCATCTGGACAT.

RNA extraction and RT–qPCR

Total RNA was extracted following instructions of the RNeasy Mini Kit (Qiagen), and then, 1 μg of RNA was reverse-transcribed into cDNA using the High-Capacity RNA-to-cDNA Kit (Thermo Scientific). Each qPCR contained 10× diluted cDNA, 0.2 μM primers, and SYBR Green Master Mix (Roche, 4913914 001).

DNA extraction

Genomic DNA was extracted either by proteinase K, RNase A, and phenol/chloroform followed by ethanol precipitation or following instructions of DNA Blood and Tissue Kit (Qiagen).

Chromatin immunoprecipitation (ChIP)

Cells were cross-linked for 12 min with 1% formaldehyde and then washed with cold PBS. The cells were centrifuged, and the pellet re-suspended in cell lysis buffer (5 mM PIPES pH 8, 85 mM
KCl, 0.5% NP40, and protease inhibitors). Cells were pelleted again and re-suspended in nucleus lysis buffer (50 mM Tris pH 8, 10 mM EDTA, 1% SDS, protease inhibitors). Cells were sonicated using a Bioruptor, and IPs were set up with around 30 µg of DNA per condition with an overnight incubation of the desired antibody. Magnetic beads (Dynabeads, Life Technologies) were added for 2 h. The beads were washed with a low salt buffer (150 mM NaCl, 1% Triton X-100, 0.1% SDS), a high salt buffer (500 mM NaCl, 1% Triton X-100, 0.1% SDS), followed by a lithium salt buffer (0.25 M LiCl, 1% NP40, 1% deoxycholic acid). Chromatin was eluted (1% SDS, 0.1 M NaHCO3 solution), and the cross-linked chromatin was reversed at 65°C overnight. The DNA was treated with RNaseA (10 mg/ml for 1 h) and proteinase K (10 mg/ml for 1 h at 50°C), followed by phenol–chloroform purification and ethanol precipitation. The DNA obtained from ChIP was denatured and biotied onto nylon membranes using a slot blot apparatus, cross-linked, and hybridized with different radioactively labeled probes. The membranes were exposed onto phosphorimager screens, and the signal intensity was quantified with ImageQuant software.

**Telomere fusion assay**

We performed telomere fusion assay as described before [23,24] with some modifications. Shortly, genomic DNA was digested with EcoRI (Promega), and accurate concentrations were measured using Qubit fluorometer (Thermo Fisher Scientific). PCRs were performed with a mix of three subtelomeric primers (21q1, 16p1, and XpYpM; 0.2 µM final concentration each) and the FailSafe™ PCR System (Lucigen) under the following conditions: 26 cycles of 94°C for 15 s, 58°C for 30 s, and 68°C for 10 min. PCR products were resolved on 0.8% agarose gels followed by Southern blotting. The PCR products, generated by the telomere fusion assay (shControl and shRAPP1 of MRC-5 senescent cells), were cleaned up with standard phenol–chloroform followed by ethanol precipitation procedures. One µg of purified DNA (per condition) was used for the preparation of libraries. DNA repair and end preparation were performed using the NEBNext FFPE DNA Repair Mix with the following reaction setup: 48 µl DNA, 3.5 µl NEBNext FFPE DNA Repair Buffer, 2 µl NEBNext FFPE DNA Repair Mix, 3.5 µl Ultra II End Prep Reaction Buffer, and 3 µl Ultra II End Prep Enzyme Mix; 20°C for 15 min followed by 65°C for 15 min. Afterward, the DNA size selection was carried out using AMPure XP Beads (NEB) followed by native barcode ligation (22.5 µl DNA, 2.5 µl native barcode provided by EXP-NBD104 kit and 25 µl Blunt/TA Ligase Master Mix; 25°C for 20 min). After another round of AMPure XP bead clean-up, the samples were pooled together and adaptors were ligated for the pooled sample at 25°C for 15 min (65 µl DNA, 5 µl AMII provided by EXP-NBD104 kit, 20 µl NEBNext Quick Ligation Reaction Buffer, and 10 µl Quick T4 DNA Ligase). The adaptor-ligated DNA was cleaned up by adding a 0.4× volume of AMPure XP beads followed by incubation for 5 min at room temperature and re-suspension of the pellet twice in 140 µl ABB solution (SQK-LSK108 kit). The purified ligated DNA was re-suspended in 15 µl Elution Buffer (SQK-LSK108 kit) and incubated with the beads for library preparation at room temperature for 10 min. The solution was centrifuged, and the supernatant was transferred to a new tube for library loading. The library was loaded on the FLO-MIN106 MinION flow cell according to the manufacturer’s guidelines (SQK-LSK108 kit). MiniON sequencing was performed by Oxford Nanopore Technologies MinKNOW software.

**Nanopore sequencing analysis**

The raw nanopore reads were processed using the 00_Long_Reads module of the LRSDay v1.5.0 framework [34]. Briefly, we performed base calling and debarcoding with Guppy v2.3.5. The debarcoded reads were further processed by Porechop v0.2.4 (https://github.com/rwrick/Porechop) for adapter trimming (option: -discard_middle). For each sample, the trimmed reads were mapped (option: -ax map-ont) to the human reference genome (version GRCh38) with minimap2 v2.16 [35]. The resulting BAM file was further processed by SAMtools v1.9 [36] and picard tools v2.18.23 (https://broadinstitute.github.io/picard/) for alignment sorting, filtering (minimal mapping quality cutoff: 30), and duplicates removing. Chimeric reads (i.e., different parts of the same read were uniquely mapped to different genomic regions) were extracted by SAMtools by only keeping the reads with the “SA:” SAM format
flag. The resulting chimeric reads were further filtered to only keep those mapped to the 20-kb most terminal regions of the human chromosomes (after removing the polyNs at the ends of the corresponding chromosomes). A final round of manual inspection was performed to verify the chimeric nature of these reads by searching them against the human reference genome using BLAT v36 (Kent 2002 Genome Research) and verified the matched regions (see Table EV1 for more details).

**Telomere length analysis by Southern blotting**

Total DNA was digested with HinfI/RsaI enzymes (Promega), and 5 μg was migrated on 1% agarose gels. After transfer of DNA to the N+ Hybond membrane (GE Healthcare), each membrane was hybridized with the telomeric DNA probe (purified 650-bp telomeric fragment) obtained by random priming using the Klenow large fragment and radioactively labeled (α32P) dCTP nucleotides. The signal was later revealed using the Typhoon FLA 9500 (GE Healthcare Life Sciences). The signal profile and the telomere length of the highest intensity peak were obtained using the ImageQuant RL 8.1 software (GE Healthcare Life Sciences).

**Telomere overhang assay**

The overhang assay was performed as described by Ref [12]. Briefly, 5 μg of genomic DNA from HeLa cells was digested with HinfI and RsaI (Promega), and incubated with 0.2 pmol of the radioactively end-labeled single-stranded (CCCTAA)3 probe overnight at 50°C. Hybridized samples were loaded into 0.9% agarose gels and size separated by electrophoresis (6 V/cm for 75 min). The gel was then dried on 3-mm paper for 4 h at 40°C and exposed on a phosphorimager screen. Telomere overhang signal was normalized to the total telomere signal, which was obtained by hybridization of the same gel but after denaturation and using the same probe as the native gel. Analysis was performed using the Typhoon FLA 9500 (GE Healthcare Life Sciences).

**Western blotting**

Protein extracts were obtained by lysis in ice-cold RIPA buffer for 30 min followed by 30-min centrifugation at 4°C. Proteins were separated on 4–20% acrylamide gradient SDS gels (Bio-Rad) and transferred to Amersham Protran 0.45-μm nitrocellulose membranes (GE Healthcare Life Sciences) for 90 min at 20% acrylamide. Further, the membranes were blocked in 5% skim milk in PBST buffer and incubated thereafter with the primary and secondary antibodies. Membranes were developed using the Luminata Forte HRP substrate (Millipore) and exposed in the Fusion Solo apparatus (Vilber Lourmat).

**IF-FISH**

Immunofluorescence–FISH in MRC-5 cells and further analysis of the images were performed as described in Ref [37]. Shortly, cells were grown on coverslips, and after determined by the specific assay time, they were fixed in 4% formaldehyde followed by permeabilization in 0.5% Triton X-100. Afterward, FISH was performed: Cells were dehydrated in ethanol and further incubated for at least 2 h with the denatured telomeric PNA probe Cy3-OO-CCCTAACCCT AACCTAA. Post-hybridization washes were performed with 70% formamide, 10 mM Tris pH 7.2, followed by wash with 50 mM Tris pH 7.5, 150 mM NaCl, 0.05% Tween-20. Next, cells were blocked in 3% BSA, 0.3% Triton X-100, and hybridized subsequently with primary and secondary antibodies mentioned above.

**Metaphase chromosome analysis**

To obtain chromosome spreads, HeLa cells, treated selectively with BIBR1532 and doxycycline as described above, were arrested in metaphase using 50 ng/ml colcemid (KaryoMAX, Invitrogen) for 2 h at 37°C. Afterward, trypsinized cells were incubated with hypotonic solution (75 mM KCl) for 15 min at 37°C, fixed with ice-cold methanol: glacial acetic acid (3:1), and spread on slides. FISH with the telomeric PNA probe was performed as described above. Stained metaphase chromosomes were visualized on the Zeiss Axiovert Z2 epi-fluorescent microscope and analyzed using the metasystem ISIS software.

**Apoptosis and senescence-associated β-galactosidase (SA-β-gal) assay**

The detection of apoptotic cells was performed using the Apoptosis/Necrosis Assay Kit (Abcam, ab176749), while the detection of SA-β-gal-positive cells was carried out using the Senescence Detection Kit (Abcam, ab65351) following the manufacturer’s instructions.

**EdU staining**

Click-it® EdU Imaging Kit (Thermo Scientific) was used to score the percentage of proliferating MRC-5 cells. Images were taken with the DeltaVision widefield deconvolution microscope (GE Healthcare).

**Statistics**

Statistical analysis was performed using the Prism 5 software (GraphPad). For comparison of two groups, we used two-tailed Mann–Whitney U-test or Student’s t-test, and for multiple groups, the Kruskal–Wallis test was used. P < 0.05 were considered significant (*P < 0.01, **P < 0.001, ***P < 0.0001).

**Data availability**

Nanopore sequencing data generated in this study are available in the Sequence Read Archive (SRA) repository (https://www.ncbi.nlm.nih.gov/sra/PRJNA577013), accession code: PRJNA577013.

**Expanded View** for this article is available online.

**Acknowledgements**

This work was performed using the genomic, PICIM, and CYTOMED facilities of IRCAN (supported by FEDER, ARC, le Ministère de l’Enseignement Supérieur, la région Provence Alpes-Côte d’Azur, and Inserm). The exchanges between the EG and JY laboratory were supported by the PHC Cai Yuanpei program of the Ministry of Foreign Affair. The work in EG laboratory was supported by grants from the Fonation ARC ("Programme Labellisé"), ANR (program TEOCHROM) Institut Nationale du Cancer (INCa) [program REPLITOP], “Investments for the Future” LABEX SIGNALIFE (reference ANR-11-LABX-0028-01), FRM grant...
Author contributions
LL and AM-B conducted most of the experiments; J-YX, JL, and GL performed and analyzed Nanopore sequencing; MJ-C-P conducted telomere overhang assay and revised manuscript; ZS provided the HeLa CRISPR cellular system; NJR helped to set up the PCR-fusion assay; JY, EG, and AM-B coordinated the study and designed experiments; and LL, EC, and AM-B wrote the manuscript.

Conflict of interest
The authors declare that they have no conflict of interest.

References
1. Li B, Oestreich S, de Lange T (2000) Identification of human Rap1: implications for telomere evolution. Cell 101: 471 – 483
2. Giraud-Panis MJ, Pisano S, Benaroch-Popivker D, Pei B, Le Du MH, Gilson E (2013) One identity or more for telomeres? Front Oncol 3: 48
3. Pardo B, Marcand S (2005) Rap1 prevents telomere fusions by non-homologous end joining. EMBO J 24: 3117 – 3127
4. Marcand S, Pardo B, Gratias A, Cahun S, Callebaut I (2008) Multiple pathways inhibit NHEJ at telomeres. Genes Dev 22: 1153 – 1158
5. Sfeir A, Kabir S, van Overbeek M, Celli GB, de Lange T (2010) Loss of Rap1 induces telomere recombination in the absence of NHEJ or a DNA damage signal. Science 327: 1657 – 1661
6. Kabir S, Hockemeyer D, de Lange T (2014) TALEN gene knockouts reveal no requirement for the conserved human shelterin protein Rap1 in telomere protection and length regulation. Cell Rep 9: 1273 – 1280
7. Rai R, Chen Y, Lei M, Chang S (2016) TRF2-RAP1 is required to protect telomeres from engaging in homologous recombination-mediated deletions and fusions. Nat Commun 7: 10881
8. Bae NS, Baumann P (2007) A RAP1/TRF2 complex inhibits nonhomologous end-joining at human telomeric DNA ends. Mol Cell 26: 323 – 334
9. Sarthy J, Bae NS, Scafrold J, Baumann P (2009) Human Rap1 inhibits non-homologous end joining at telomeres. EMBO J 28: 3900 – 3909
10. Bombarde O, Boby C, Gomez D, Frit P, Giraud-Panis MJ, Gilson E, Salles B, Calisou P (2010) TRF2/RAP1 and DNA-PK mediate a double protection against joining at telomeric ends. EMBO J 29: 1573 – 1584
11. Martinez P, Gomez-Lopez G, Pisano OG, Flores JM, Blasco MA (2016) A genetic interaction between RAP1 and telomerase reveals an unanticipated role for RAP1 in telomere maintenance. Aging Cell 15: 1113 – 1125
12. Benaroch-Popivker D, Pisano S, Mendez-Bermudez A, Lototska L, Kaur P, Bauwens S, Djerbi N, Latrick CM, Fraisier V, Pei B et al (2016) TRF2-mediated control of telomere DNA topology as a mechanism for chromosome-end protection. Mol Cell 61: 274 – 286
13. Fujita K, Horikawa I, Mondal AM, Jenkins LM, Appella E, Vojetsek B, Bourdon JC, Lane DP, Harris CC (2010) Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol 12: 1205 – 1212
14. Luo Z, Feng X, Wang H, Xu W, Zhao Y, Ma W, Jiang S, Liu D, Huang J, Songyang Z (2015) Mir-23a induces telomere dysfunction and cellular senescence by inhibiting TRF2 expression. Aging Cell 14: 391 – 399
15. Wagner KD, Ying Y, Leong W, Jiang J, Hu X, Chen Y, Michiels JF, Lu Y, Gilson E, Wagner N et al (2017) The differential spatiotemporal expression pattern of shelterin genes throughout lifespan. Aging 9: 1219 – 1232
16. Swanson MJ, Baribault ME, Israel JN, Bae NS (2016) Telomere protein Rap1 levels are affected by cellular aging and oxidative stress. Biomed Rep 5: 181 – 187
17. Takai KK, Hooper S, Blackwood S, Gandhi R, de Lange T (2010) In vivo stoichiometry of shelterin components. J Biol Chem 285: 1457 – 1467
18. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM (2004) Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 14: 501 – 513
19. Kaul Z, Cesare AJ, Hruschtscha L, Neumann AA, Reddel RR (2011) Five dysfunctional telomeres predict onset of senescence in human cells. EMBO Rep 13: S2 – S9
20. Suzuki M, Suzuki K, Kodama S, Yamashita S, Watanabe M (2012) Persistent amplification of DNA damage signal involved in replicative senescence of normal human diploid fibroblasts. Oxid Med Cell Longev 2012: 310534
21. Fumagalli M, Rossielli F, Mondello C, d’Adda di Fagagna F (2014) Stable cellular senescence is associated with persistent DDR activation. PLoS ONE 9: e110969
22. Martinez P, Thanasoulas M, Carlos AR, Gomez-Lopez G, Tejera AM, Schoettner S, Dominguez Q, Pisano OG, Tarsounas M, Blasco MA (2010) Mammalian Rap1 controls telomere function and gene expression through binding to telomeric and extratelomeric sites. Nat Cell Biol 12: 768 – 780
23. Capper R, Britt-Compton B, Tankimanova M, Rowson J, Letsolo B, Man S, Haughton M, Baird DM (2007) The nature of telomere fusion and a definition of the critical telomere length in human cells. Genes Dev 21: 2495 – 2508
24. Letsolo BT, Rowson J, Baird DM (2010) Fusion of short telomeres in human cells is characterized by extensive deletion and microhomology, and can result in complex rearrangements. Nucleic Acids Res 38: 1841 – 1852
25. Oh S, Harvey A, Zimbic J, Wang Y, Nguyen T, Jackson PJ, Hendrickson EA (2014) DNA ligase III and DNA ligase IV carry out genetically distinct forms of end joining in human somatic cells. DNA Repair 21: 97 – 110
26. Kim H, Li F, He Q, Deng T, Xu J, Jin F, Caofia C, Putluri N, Liu D, Songyang Z (2017) Systematic analysis of human telomeric dysfunction using inducible telomere/shelterin CRISPR/Cas9 knockout cells. Cell Discov 3: 17034
27. Dimitrova N, Chen YC, Spector DL, de Lange T (2008) S3BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility. Nature 456: 524 – 528
28. Lottersberger F, Karssenmeyer RA, Dimitrova N, de Lange T (2015) S3BP1 and the LINC complex promote microtubule-dependent DSBR mobility and DNA repair. Cell 163: 880 – 893
29. Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Alvarez-Quilon A, Moatti N, Zimmermann M et al (2018) The shieldin complex mediates S3BP1-dependent DNA repair. Nature 560: 117 – 121
30. Mirman Z, Lottersberger F, Takai H, Kibe T, Gong Y, Takai K, Bianchi A, Zimmermann M, Durocher D, de Lange T (2018) S3BP1-RIF1-shieldin counteracts DSBR resection through CST- and Polalpha-dependent fill-in. Nature 560: 112 – 116
31. Beausejour CM, Krölica A, Galimi F, Narita M, Lowe SW, Yaswen P, Campisi J (2003) Reversal of human cellular senescence: roles of the p53 and p16 pathways. *EMBO J* 22: 4212–4222
32. Chang M, Arneric M, Lingner J (2007) Telomerase repeat addition processivity is increased at critically short telomeres in a Tel1-dependent manner in *Saccharomyces cerevisiae*. *Genes Dev* 21: 2485–2494
33. Baird DM, Rowson J, Wynford-Thomas D, Kipling D (2003) Extensive allelic variation and ultrashort telomeres in senescent human cells. *Nat Genet* 33: 203–207
34. Yue JX, Liti G (2018) Long-read sequencing data analysis for yeasts. *Nat Protoc* 13: 1213–1231
35. Li H (2018) Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* 34: 3094–3100
36. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S (2009) The sequence alignment/map format and SAMtools. *Bioinformatics* 25: 2078–2079
37. Mendez-Bermudez A, Lototska L, Bauwens S, Giraud-Panis MJ, Croce O, Jamet K, Irizar A, Mowinckel M, Koundrioukoff S, Nottet N et al (2018) Genome-wide control of heterochromatin replication by the telomere capping protein TRF2. *Mol Cell* 70: 449–461 e5

License: This is an open access article under the terms of the Creative Commons Attribution 4.0 License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.